What is it about?
Evidence based review of safinamide for formulary committees
Featured Image
Why is it important?
New type of treatment for patient's with Parkinson's disease with off episodes
Perspectives
Adjunct medication to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing off episodes. Evidence of efficacy during first part of therapy but therapeutic benefitmay diminish over time. Long-term safety data indicate that safinamide is safe to use, at least up to 2 years. No head-to-head trials with other selective MAO-B inhibitors.
Danial Baker
Washington State University
Read the Original
This page is a summary of: Formulary Drug Review: Safinamide, Hospital Pharmacy, August 2017, SAGE Publications,
DOI: 10.1177/0018578717726046.
You can read the full text:
Contributors
The following have contributed to this page
